DermTech Inc
| NASDAQ: DMTK |
| Healthcare / Medical Diagnostics & Research / USA |
| 6.50 | +0.2700 | +4.33% | Vol 2.95M | 1Y Perf -86.16% |
| Jun 24th, 2022 16:00 DELAYED |
| BID | 5.70 | ASK | 6.76 | ||
| Open | 6.33 | Previous Close | 6.23 | ||
| Pre-Market | - | After-Market | 6.50 | ||
| - - | - -% |
| Target Price | 26.75 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | 311.54 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | ★★★★ 56.48 | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Price Range Ratio 52W % | 5.26 | Earnings Rating | — | |
| Market Cap | 194.61M | Earnings Date | 3rd Aug 2022 | |
| Alpha | 0.00 | Standard Deviation | 0.29 | |
| Beta | 1.15 |
Today's Price Range 6.126.55 | 52W Range 4.1848.32 |
Summary:
Neutral
| Technical Indicators: | Buy |
| Moving Averages: | Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | 35.42% | ||
| 1 Month | 1.25% | ||
| 3 Months | -50.27% | ||
| 6 Months | -63.81% | ||
| 1 Year | -86.16% | ||
| 3 Years | -68.45% | ||
| 5 Years | - | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -36.67 | |||
ROE last 12 Months | -40.57 | |||
ROA (5Y Avg) | -9.89 | |||
ROA last 12 Months | -37.01 | |||
ROC (5Y Avg) | -25.67 | |||
ROC last 12 Months | -38.67 | |||
Return on invested Capital Q | -13.00 | |||
Return on invested Capital Y | -10.49 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 2.60 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -1.50 | ||||
| 0.71 | ||||
| 11.03 | ||||
| - | ||||
| -1.80 | ||||
| -2.58 | ||||
| 0.71 | ||||
| 6.80 | ||||
| -32 087 900.00 | ||||
| Forward PE | - | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 14.20 | ||||
| 14.40 | ||||
| 0.10 | ||||
| 0.11 | ||||
| -73.90 | ||||
| Leverage Ratio | 1.10 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 7.00 | ||||
| -722.70 | ||||
| -702.60 | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 13.03M | ||||
| 0.44 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q01 2022 | -0.85 | -1.01 | -18.82 |
| Q04 2021 | -0.73 | -0.88 | -20.55 |
| Q03 2021 | -0.65 | -0.68 | -4.62 |
| Q02 2021 | -0.54 | -0.48 | 11.11 |
| Q01 2021 | -0.47 | -0.49 | -4.26 |
| Q04 2020 | -0.54 | -0.48 | 11.11 |
| Q03 2020 | -0.58 | -0.50 | 13.79 |
| Q04 2019 | - | -0.08 | - |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Next Report Date | 3rd Aug 2022 |
| Estimated EPS Next Report | -1.02 |
| Estimates Count | 1 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 2.95M |
| Shares Outstanding | 29.94K |
| Shares Float | 22.85M |
| Trades Count | 9.43K |
| Dollar Volume | 19.09M |
| Avg. Volume | 1.30M |
| Avg. Weekly Volume | 1.90M |
| Avg. Monthly Volume | 1.10M |
| Avg. Quarterly Volume | 891.95K |
DermTech Inc (NASDAQ: DMTK) stock closed at 6.5 per share at the end of the most recent trading day (a 4.33% change compared to the prior day closing price) with a volume of 2.95M shares and market capitalization of 194.61M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Diagnostics & Research industry, Healthcare sector and employs 64 people. DermTech Inc CEO is John D Dobak.
The one-year performance of DermTech Inc stock is -86.16%, while year-to-date (YTD) performance is -58.86%. DMTK stock has a five-year performance of %. Its 52-week range is between 4.18 and 48.32, which gives DMTK stock a 52-week price range ratio of 5.26%
DermTech Inc currently has a PE ratio of -1.50, a price-to-book (PB) ratio of 0.71, a price-to-sale (PS) ratio of 11.03, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -37.01%, a ROC of -38.67% and a ROE of -40.57%. The company’s profit margin is -%, its EBITDA margin is -702.60%, and its revenue ttm is $13.03 Million , which makes it $0.44 revenue per share.
Of the last four earnings reports from DermTech Inc, there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-1.02 for the next earnings report. DermTech Inc’s next earnings report date is 03rd Aug 2022.
The consensus rating of Wall Street analysts for DermTech Inc is Strong Buy (1), with a target price of $26.75, which is +311.54% compared to the current price. The earnings rating for DermTech Inc stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
DermTech Inc has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
DermTech Inc has a Neutral technical analysis rating based on Technical Indicators (ADX : 30.86, ATR14 : 0.65, CCI20 : 52.79, Chaikin Money Flow : 0.21, MACD : -0.54, Money Flow Index : 65.60, ROC : 2.20, RSI : 52.33, STOCH (14,3) : 89.58, STOCH RSI : 1.00, UO : 63.77, Williams %R : -10.42), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of DermTech Inc in the last 12-months were:
DermTech Inc
DermTech Inc is an emerging growth molecular diagnostic company. The company is engaged in marketing and developing novel non-invasive genomic tests to aid in the diagnosis of various skin conditions, including skin cancer, inflammatory diseases, and aging-related conditions. While the company generates revenue through laboratory services.
CEO: John D Dobak
Telephone: +1 858 450-4222
Address: 11099 N. Torrey Pines Road, La Jolla 92037, CA, US
Number of employees: 64
